Vanguard Global Advisers’s Bright Minds Biosciences DRUG Stock Holding History
Bought
Maintained
Sold
Other funds holding DRUG
Vanguard Global Advisers's DRUG Position: Q3 2026 in Review
Vanguard Global Advisers reduced its Bright Minds Biosciences (DRUG) stake by 99% in Q3 2026, selling an estimated $271K and leaving 32 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #3682.
Vanguard Global Advisers first reported a position in DRUG in Q1 2026 and has held it in 3 quarters since. The position peaked at $272K in Q2 2026. 110 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.
- Vanguard Global Advisers held 32 shares of Bright Minds Biosciences worth $1.59K as of Q3 2026.
- Vanguard Global Advisers sold 3,838 Bright Minds Biosciences shares in Q3 2026, an estimated $271K.
- Bright Minds Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3682 holding.
- Vanguard Global Advisers first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Bright Minds Biosciences position peaked at $272K in Q2 2026.
- 110 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.